- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model VUF11207 ...
MedChemExpress - Model VUF11207 fumarate -1785665-61-3
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation[1].MCE products for research use only. We do not sell to patients.
VUF11207 fumarate
MCE China：VUF11207 fumarate
Brand：MedChemExpress (MCE)
Cat. No.HY-110318
CAS：1785665-61-3
Purity：98.28%
Storage：4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Shipping：Room temperature in continental US; may vary elsewhere.
Description：VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation.
In Vitro：VUF11207 fumarate (0.17 nM; 5 days) inhibits RANKL‑ and TNF‑α‑induced osteoclastogenesis through CXCL12 inhibition in osteoclast precursor cells[1]. VUF11207 fumarate inhibits osteoclastogenesis by suppressing phosphorylation of erk[1].
In Vivo：VUF11207 fumarate (100 µg/day; s.c.; single daily for 5 days) inhibits LPS‑induced osteoclastogenesis, bone resorption and production of RANKL and TNF‑α in mice[1].
IC50 & Target：CXCR7 8.1 (pKi)
Hot selling product：LY2109761 | Fludarabine | Norepinephrine | Tucatinib | BzATP (triethylammonium salt) | Sinefungin | AP1867 | PLGA (50:50) | Avelumab | Luteolin
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92. [Content Brief]
[2]. Nugraha AP, et al. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25(3):78. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。